Iovance Biotherapeutics Performance dei guadagni passati
Il passato criteri di controllo 0/6
Iovance Biotherapeutics's earnings have been declining at an average annual rate of -18.9%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been growing at an average rate of 106.9% per year.
Informazioni chiave
-18.9%
Tasso di crescita degli utili
-5.5%
Tasso di crescita dell'EPS
| Biotechs Crescita del settore | 17.0% |
| Tasso di crescita dei ricavi | 106.9% |
| Rendimento del capitale proprio | -57.3% |
| Margine netto | -1,343.3% |
| Prossimo aggiornamento sui guadagni | 07 Nov 2024 |
Aggiornamenti sulle prestazioni recenti
Recent updates
Iovance Biotherapeutics: Moving To The Next Phase
Oct 03Iovance Therapeutics: Historic Product, Tough Commercial Outlook
Sep 06Earnings Update: Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Just Reported And Analysts Are Boosting Their Estimates
Aug 11
Iovance's Tumor-Fighting TILs Are Just Warming Up (Rating Upgrade)
Aug 11Iovance Biotherapeutics: Amtagvi Launch Continues Upward
Jun 26Iovance Q1 Earnings Review: Not Enough Data To Draw Conclusions On Amtagvi
May 10Iovance Biotherapeutics: Riding The Favorable Moment Could Bring Excellent Results
Apr 09Iovance Biotherapeutics: Initial Amtagvi Launch In Focus
Mar 25Iovance Biotherapeutics: Amtagvi's Pioneering Approval Sets New Standards In Melanoma
Feb 20Iovance Biotherapeutics: Preparing For Volatility Around Lifileucel's Upcoming PDUFA Date
Jan 19Iovance Biotherapeutics Approaches Key Regulatory Milestone As Clinical Momentum Accelerates
Sep 27Iovance submits rolling license application to FDA for skin cancer treatment lifileucel
Aug 25Calculating The Fair Value Of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Aug 25Iovance Biotherapeutics falls 6% on Q2 2022 bottom line miss
Aug 04Iovance: TIL Cell Therapy Set To Prove Itself
Jul 11Iovance: Onward To Approval
Apr 20Iovance Biotherapeutics: An Unproven Biopharmaceutical Company With Significant Upside
Mar 25Ripartizione dei ricavi e delle spese
Come Iovance Biotherapeutics guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.
Storia dei guadagni e delle entrate
| Data | Ricavi | Guadagni | Spese G+A | Spese di R&S |
|---|---|---|---|---|
| 30 Jun 24 | 33 | -440 | 128 | 317 |
| 31 Mar 24 | 2 | -450 | 110 | 341 |
| 31 Dec 23 | 1 | -444 | 107 | 344 |
| 30 Sep 23 | 1 | -433 | 103 | 337 |
| 30 Jun 23 | 0 | -419 | 104 | 322 |
| 31 Mar 23 | 0 | -412 | 109 | 309 |
| 31 Dec 22 | 0 | -396 | 104 | 295 |
| 30 Sep 22 | 0 | -390 | 101 | 290 |
| 30 Jun 22 | 0 | -376 | 94 | 283 |
| 31 Mar 22 | 0 | -358 | 87 | 271 |
| 31 Dec 21 | 0 | -342 | 84 | 259 |
| 30 Sep 21 | 0 | -311 | 76 | 236 |
| 30 Jun 21 | 0 | -284 | 71 | 214 |
| 31 Mar 21 | 0 | -265 | 66 | 201 |
| 31 Dec 20 | 0 | -260 | 60 | 202 |
| 30 Sep 20 | 0 | -255 | 55 | 204 |
| 30 Jun 20 | 0 | -246 | 49 | 202 |
| 31 Mar 20 | 0 | -230 | 46 | 192 |
| 31 Dec 19 | 0 | -198 | 41 | 166 |
| 30 Sep 19 | 0 | -167 | 38 | 139 |
| 30 Jun 19 | 0 | -151 | 35 | 126 |
| 31 Mar 19 | 0 | -134 | 31 | 111 |
| 31 Dec 18 | 0 | -124 | 28 | 100 |
| 30 Sep 18 | 0 | -117 | 26 | 93 |
| 30 Jun 18 | 0 | -105 | 25 | 82 |
| 31 Mar 18 | 0 | -98 | 23 | 76 |
| 31 Dec 17 | 0 | -92 | 21 | 72 |
| 30 Sep 17 | 0 | -82 | 13 | 61 |
| 30 Jun 17 | 0 | -128 | 17 | 53 |
| 31 Mar 17 | 0 | -116 | 20 | 38 |
| 31 Dec 16 | 0 | -102 | 17 | 27 |
| 30 Sep 16 | 0 | -95 | 25 | 21 |
| 30 Jun 16 | 0 | -34 | 18 | 17 |
| 31 Mar 16 | 0 | -29 | 12 | 17 |
| 31 Dec 15 | 0 | -28 | 12 | 15 |
| 30 Sep 15 | 0 | -24 | 10 | 14 |
| 30 Jun 15 | 0 | -19 | 10 | 9 |
| 31 Mar 15 | 0 | -15 | 9 | 6 |
| 31 Dec 14 | 0 | -12 | 8 | 4 |
| 30 Sep 14 | 0 | -27 | 7 | 2 |
| 30 Jun 14 | 0 | -34 | 7 | 2 |
| 31 Mar 14 | 0 | -35 | 6 | 1 |
Guadagni di qualità: IOVA is currently unprofitable.
Margine di profitto in crescita: IOVA is currently unprofitable.
Flusso di cassa libero e analisi degli utili
Analisi della crescita degli utili nel passato
Andamento degli utili: IOVA is unprofitable, and losses have increased over the past 5 years at a rate of 18.9% per year.
Accelerare la crescita: Unable to compare IOVA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Guadagni vs Settore: IOVA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
Rendimento del capitale proprio
ROE elevato: IOVA has a negative Return on Equity (-57.28%), as it is currently unprofitable.